Rise in incidence of endometriosis is responsible for the
notable growth of the endometriosis treatment market. As there are
a handful of relieving procedures available, there is a scope for
extensive research in this regard. Several clinical trials are
being conducted with the objective of having a robust line of
treatment in place.
WILMINGTON, Del., July 26, 2024 /PRNewswire/ -- The market for
endometriosis treatment is projected to attain a value
of US$ 3.1
billion by 2034. According to Transparency Market
Research, the landscape was valued at US$
1.4 billion in 2023. From 2024 to 2034, the market is
anticipated to advance at a CAGR of 7.5%. Peritoneal
and ovarian endometriosis treatments are well established, with
laparoscopic cystectomy for ovarian endometriomas outperforming
drainage and electrocoagulation.
Hormone therapies such as GnRH agonists and antagonists,
aromatase inhibitors, and other hormonal medicines, are crucial in
controlling endometriosis-related pain. Newer medications, such as
GnRH antagonists like Elagolix and Letrozole, have showed promise,
especially in terms of pain relief and fertility outcomes.
Despite the range of treatment choices, the market faces
obstacles in providing effective long-term solutions that do not
jeopardize fertility. Drugs such as Elagolix, which was licensed by
the FDA in 2018, have considerable potential but require additional
investigation, particularly in terms of its usage in pre-treatment
prior to in vitro fertilization. Elagolix's ongoing clinical
research (NCT04173169) is expected to provide useful insights once
completed in September 2024.
Request a PDF Sample of this Report
Now
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20834
The market is also looking into selective estrogen receptor
modulators (SERMs), such as SR-16234, which show promise due to
their unique receptor action but require further clinical
validation. Furthermore, established treatments like Danazol are
still being contested due to their negative effects, whereas
medications like Gestrinone are less often used and unavailable in
areas such as the United
States.
Key Takeaways from the Market Study
- The global endometriosis treatment market is poised to garner a
valuation of US$ 1.5 billion in
2024.
- From 2024 to 2034, the market is poised to expand more than
2x.
- Hormone therapy remains the most preferred treatment type for
endometriosis.
- By drug class, gonadotropin-releasing Hormone (Gn-RH) agonists
and antagonists to be most preferred.
Key Drivers and Trends
- The endometriosis treatment market is expected to rise, owing
to developments in both surgical procedures and pharmaceutical
innovations.
- The focus on finding medicines that do not impair fertility
remains a major field of study, with hopeful implications for
future market developments. As our understanding of endometriosis
grows, the market will likely see more targeted and effective
treatment choices, hence increasing the quality of life for
affected women.
- There are various drugs in pipeline regarding endometriosis
treatment. Furthermore, government and non-government agencies are
also supporting research on this count.
- In February 2021, the
DBT/Wellcome India Alliance announced that it would extend support
to a major national research project called 'Endometriosis Clinical
and Genetic Research in India
(ECGRI)', which aimed to widen understanding of genetic risks and
clinical phenotypes related to endometriosis.
Endometriosis Treatment Market Report Scope:
Report
Coverage
|
Details
|
Forecast
Period
|
2024-2034
|
Base
Year
|
2020-2022
|
Size in 2023
|
US$ 1.4 Bn
|
Forecast (Value) in
2034
|
US$ 3.1 Bn
|
Growth Rate
(CAGR)
|
7.5 %
|
No. of
Pages
|
156
Pages
|
Segments
covered
|
By Treatment Type, By
Drug Class, By Distribution Channel, By Region
|
Unlock Growth Potential in Your Industry Download PDF
Brochure:
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=20834
Key Regions Profiled
- North America dominates the
endometriosis therapy landscape and the dominance is expected to
remain unchanged during the forecast period. This is attributed to
rise in incidence of endometriosis followed by increasing awareness
regarding the same.
- For instance, as per the data published by the Office on
Women's Health in 2021, endometriosis ends up affecting over 11% of
women aged between 15 and 44.
- Asia Pacific's endometriosis
treatment market growth is ascribed to a noticeable upswing in the
number of patients suffering from endometriosis coupled with
increasing R&D activities in this regard.
Competitive Landscape
Players in the endometriosis treatment landscape are seeking
fast track approvals for their products from regulatory
authorities. Given the highly complex nature of this treatment,
providers have to comply with stringent guidelines before they make
the said approach available to end users. Some prominent
endometriosis treatment providers are given below:
- AbbVie Inc.
- AstraZeneca plc
- Bayer AG
- Ferring Pharmaceuticals
- Johnson & Johnson
- Myovant Sciences Ltd.
- Pfizer Inc.
- The Takeda Pharmaceutical Company Limited
- Lannett Co Inc.
- Teva Pharmaceutical Industries Ltd.
Key Developments
- In August 2022, Myovant
Sciences and Pfizer announced that the U.S. FDA had
approved MYFEMBREE meant for managing moderate-to-severe pain
linked with endometriosis in the pre-menopausal women.
- In February 2022,
ObsEva SA announced that it had inked a strategic licensing
agreement with Theramex in order to extend support to
commercialization of linzagolix across the markets out of the
U.S.
- In January 2022,
ObsEva announced positive results from Phase 3 EDELWEISS 3
trial of linzagolix, one of the oral Gn-RH antagonists, in women
suffering from moderate-to-severe endometriosis-associated pain
(EAP).
Segments Profiled
Treatment Type
- Pain Medication
- Hormone Therapy
Drug Class
- Hormonal Contraceptives
- Gonadotropin-releasing Hormone (Gn-RH) Agonists and
Antagonists
- Progestin Therapy
- Aromatase Inhibitors
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Purchase the Report for Market-Driven Insights:
https://www.transparencymarketresearch.com/checkout.php?rep_id=20834<ype=S
More Trending Report by Transparency Market Research:
- Infant Resuscitators Market - The global infant
resuscitators market was valued at US$ 253.1
million in 2022. It is projected to grow at a compound
annual growth rate (CAGR) of 5.2% from 2023 to 2031, reaching over
US$ 401.4 million by the end of
2031.
- Mechanical Thrombectomy Devices Market - The mechanical
thrombectomy devices market was valued at US$ 1.1 billion in 2022. It is expected to grow
at a CAGR of 6.4% from 2023 to 2031, reaching over US$ 1.8 billion by the end of 2031.
- Sanitization Robots Market- The sanitization robots
market was valued at US$ 927.3
million in 2022. It is projected to advance at an impressive
CAGR of 19.2% from 2023 to 2031, reaching over US$ 4.8 billion by 2031.
- Microcatheter Market - The global microcatheter market
was valued at US$ 799.7 million in
2022. It is estimated to grow at a CAGR of 5.3% from 2023 to 2031,
reaching approximately US$ 1.3
billion by the end of 2031.
About Transparency Market Research
Transparency Market Research, a global market
research company registered at Wilmington, Delaware, United States, provides custom research and
consulting services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insights
for thousands of decision makers. Our experienced team of Analysts,
Researchers, and Consultants use proprietary data sources and
various tools & techniques to gather and analyses
information.
Our data repository is continuously updated and revised by a
team of research experts, so that it always reflects the latest
trends and information. With a broad research and analysis
capability, Transparency Market Research employs rigorous primary
and secondary research techniques in developing distinctive data
sets and research material for business reports.
Contact:
Transparency Market Research Inc.
CORPORATE HEADQUARTER
DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware
19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free:
866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow
Us: LinkedIn| Twitter| Blog | YouTube
Logo:
https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/endometriosis-treatment-market-to-surge-to-us-3-1-billion-by-2034-innovations-in-surgical-procedures-and-fertility-preserving-medications-drive-market-growth--tmr-302207553.html